Archer Pharmaceuticals

Archer Pharmaceuticals, Inc. (Archer) was founded in 2008 and specializes in targeted drug discovery for Alzheimer’s disease. Led by Chief

Archer Pharmaceuticals, Inc. (Archer) was founded in 2008 and specializes in targeted drug discovery for Alzheimer’s disease. Led by Chief Executive Officer and Chief Scientific Officer Michael Mullan, M.B.B.S., Ph.D. and Chief Technical Officer and Associate Chief Scientific Officer Fiona Crawford, Ph.D., Archer was created based on the groundbreaking research conducted at the Roskamp Institute in Sarasota, Florida. Included in this research is clinical development of Nilvadipine as a therapeutic for Alzheimer’s Disease. A Phase I/IIA human clinical trial was conducted in Alzheimer’s patients in partnership with the Trinity College Institute of Neuroscience in Dublin, Ireland. This trial showed that Nilvadipine was well-tolerated in Alzheimer’s disease patients, and, together with extensive preclinical data in laboratory models of Alzheimer’s Disease, laid the foundation for a Phase III double-blind, placebo-controlled clinical trial of Nilvadipine (NILVAD) which is currently ongoing in Europe.